CVS Group: TVR & Confirmation of Dividend Dates

CVS Group plc

30 September 2026

 

30 September 2026

CVS Group plc

("CVS" or the "Company")

Total Voting Rights & Confirmation of Dividend Dates

CVS, the UK listed veterinary group and a leading provider of veterinary services, announces that, as of 30 September 2026, following cancellation of the Ordinary Shares purchased pursuant to the Company's share buyback programme (announced on 26 May 2026) prior to the date of this announcement, the Company's total issued share capital consists of 67,460,830 ordinary shares of 0.2p each ("Ordinary Shares").

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Confirmation of Dividend Dates

Following the announcement of the Company’s Final Results for the year ended 30 June 2026 on 24 September 2026, the Company confirms the correct dates for the final dividend as follows:

• Ex-Dividend Date: 5 November 2026
• Record Date: 6 November 2026
• Payment Date: 4 December 2026

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.